Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
about
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Partial PTEN deletion is linked to poor prognosis in breast cancerA new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathwayAmphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer.The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
P2860
Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical significance of p95HE ...... th trastuzumab-based therapies
@en
Clinical significance of p95HE ...... h trastuzumab-based therapies.
@nl
type
label
Clinical significance of p95HE ...... th trastuzumab-based therapies
@en
Clinical significance of p95HE ...... h trastuzumab-based therapies.
@nl
prefLabel
Clinical significance of p95HE ...... th trastuzumab-based therapies
@en
Clinical significance of p95HE ...... h trastuzumab-based therapies.
@nl
P2093
P2860
P356
P1476
Clinical significance of p95HE ...... th trastuzumab-based therapies
@en
P2093
E Büyükünal
F Demirelli
S Serdengecti
P2860
P2888
P304
P356
10.1038/BJC.2014.72
P407
P577
2014-03-04T00:00:00Z